**MINUTES**

**CPIC CONFERENCE CALL**

DATE: August 6, 2020

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| CPIC gene/drug pair list updates and revised CPIC level definitions | The CPIC levels posted to the CPIC website (<https://cpicpgx.org/genes-drugs/>) have been reviewed and updated per standardized criteria. New ‘in-between’ levels (e.g., B/C and C/D) have been defined to indicate a level of uncertainty around the level assignment until the gene/drug association can be formally reviewed by a CPIC author group. CPIC levels are considered final once a guideline for that gene/drug association has been written; otherwise, the assigned level is provisional and subject to change.  | All: If you have any edits to the proposed CPIC levels, email Kelly (kelly.caudle@stjude.org) with your recommendation and rationale.  |
| *CYP2C19*/PPI guideline | The new CPIC guideline for *CYP2C19* and proton pump inhibitors (PPIs) has been accepted for publication and will be available online soon. PharmGKB will write blog post about it. Congratulations to all the authors! |  |
| SSRI guideline update | The CPIC guideline for selective serotonin reuptake inhibitors (SSRIs) will be updated. Jeffrey Bishop will serve as the senior author for this guideline update. The scope of the guideline will be determined by the authors and may be expanded to also include certain SNRIs that are affected by *CYP2D6* as well as certain pharmacodynamics genes such as *SLC6A4* and *HTR2A*.  | All: If you have expertise in this area or know of someone who does, please send your nominations for authors to Kelly Caudle (kelly.caudle@stjude.org).  |
| Opioid guideline | Kristine Crews provided an overview of the draft opioid guideline. The scope of this guideline expanded considerably, as the original guideline just included *CYP2D6* and codeine, whereas the new guideline includes additional opioids (e.g., tramadol, oxycodone, hydrocodone, methadone, morphine, and fentanyl) and genes (e.g., *OPRM1* and *COMT*). This expansion required significant effort on the part of the authors, who reviewed >300 papers. There are clinically actionable recommendations for codeine and tramadol, but not for the other opioids and the other genes.  | All: Please review and provide feedback to Kelly Caudle (kelly.caudle@stjude.org) by August 28th. |
| Updates to CPIC SOPs  | Mary Relling provided an update to CPIC’s standard operating procedures (SOPs). CPIC has two primary SOPs, one for the guideline development process (up to now on member’s site only) and one for allele function assignment (posted since October 2019). Both will be publicly available on the CPIC website. The allele function assignment SOP has been piloted with the most recent CPIC guidelines. This SOP also addresses translating diplotypes into phenotypes.  | All: Email Mary Relling (mary.relling@stjude.org) with any feedback on CPIC’s SOPs. |